Comparison
Armodafinil vs Epitalon
Side-by-side of Armodafinil and Epitalon. Every row below is pulled from the compound schema and will update as our data grows. For deeper reads, follow through to each compound page.
Armodafinil
Armodafinil is the R-enantiomer sold as Nuvigil. Half-life 10-15 h, 150 mg standard dose, narcolepsy and shift-work approvals, Schedule IV.
Epitalon
Epitalon peptide (Epithalon, tetrapeptide AEDG): telomerase activation, lifespan extension data, anti-aging trials, dosage, half-life, and safety.
Effects at a glance
Armodafinil
- •FDA approved in 2007 for narcolepsy, shift-work sleep disorder, and OSA residual sleepiness
- •R-enantiomer of modafinil; 150 mg armodafinil is roughly equivalent to 200 mg modafinil
- •Schedule IV controlled in the US; prescription-only globally
- •Longer terminal half-life of about 15 hours produces extended late-day wakefulness coverage
- •Same CYP3A4 induction as modafinil; reduces hormonal contraceptive efficacy
- •Side-effect profile and dermatologic risk warnings mirror modafinil
Epitalon
- •Synthetic tetrapeptide (Ala-Glu-Asp-Gly) developed at the St. Petersburg Institute of Bioregulation
- •Russian clinical literature reports mortality reduction in elderly cohorts and improved melatonin output
- •Reported telomerase activation in human somatic cell culture and lifespan extension in mice and Drosophila
- •Independent Western replication is essentially absent; no FDA-standard RCTs
- •Anecdotal protocols use 5 to 10 mg subcutaneously daily for 10 to 20 day cycles, 2 to 4 times yearly
- •Not currently on the WADA Prohibited List
Side-by-side
| Attribute | Armodafinil | Epitalon |
|---|---|---|
| Category | pharmaceutical | peptide |
| Also known as | Nuvigil, R-modafinil, (R)-(-)-modafinil | Epithalon, Ala-Glu-Asp-Gly, AEDG, Epithalamin (precursor extract) |
| Half-life (hr) ↗ | 15 | 0.5 |
| Typical dose (mg) ↗ | 150 | 5 |
| Dosing frequency | daily, morning | daily during cycle |
| Routes | oral | subcutaneous, intramuscular, intranasal |
| Onset (hr) | 1 | 24 |
| Peak (hr) | 3 | 168 |
| Molecular weight | 273.35 | 390.35 |
| Molecular formula | C15H15NO2S | C14H22N4O9 |
| Mechanism | Weak dopamine reuptake inhibition plus downstream activation of histaminergic, noradrenergic, and orexinergic wake systems; R-enantiomer of modafinil with longer half-life. | Synthetic tetrapeptide proposed to interact directly with DNA and chromatin to modulate tissue-specific gene expression. Reported effects include telomerase activation, increased melatonin output from pineal cells, and circadian normalization. |
| Legal status | Schedule IV (US); prescription-only globally; not a supplement | Not FDA approved; registered in Russia under domestic pharmaceutical framework; research-use-only grey market in US/EU |
| WADA status | banned | unknown |
| DEA / Rx | Schedule IV | Not scheduled (research chemical) |
| Pregnancy | Not recommended | Insufficient data; not recommended |
| CAS | 112111-43-0 | 307297-39-8 |
| PubChem CID | 9148206 | 219042 |
| Wikidata | Q4791953 | Q5384126 |
Safety profile
Armodafinil
Common side effects
- headache
- nausea
- dizziness
- anxiety
- insomnia (with later-day dosing)
- dry mouth
- mild blood pressure elevation
Contraindications
- recent myocardial infarction
- unstable angina
- left ventricular hypertrophy
- significant arrhythmia
- history of Stevens-Johnson syndrome
- psychotic disorders
- pregnancy
- concurrent MAOI use
Interactions
- hormonal contraceptives: CYP3A4 induction reduces contraceptive efficacy; use barrier method(major)
- cyclosporine: reduced cyclosporine levels via CYP3A4 induction(major)
- warfarin: CYP2C9 inhibition raises INR(moderate)
- phenytoin: CYP2C19 inhibition raises phenytoin levels(moderate)
- MAOIs: potential hypertensive reaction(major)
- classical stimulants: additive cardiovascular and sleep-disruption effects(moderate)
Epitalon
Common side effects
- injection-site reactions
- occasional mild headache (rare)
Contraindications
- pregnancy
- lactation
- active malignancy (theoretical telomerase concern)
- concurrent immunosuppression
Interactions
- melatonin: potential additive effect on circadian and pineal output; no controlled data(minor)
Which Should You Take?
Armodafinil comes out ahead for most readers on the criteria we weight: 3 catalogued goals, controlled substance, oral dosing, with a Tier-A outcome catalogued. Epitalon is the right call when one of the conditionals below applies.
- → If your priority is wakefulness, pick Armodafinil.
- → If your priority is focus or working memory, pick Armodafinil.
- → If your priority is healthspan extension, pick Epitalon.
- → If your priority is sleep onset or sleep quality, pick Epitalon.
Edge case: If you cannot self-administer injections, Armodafinil is the only oral option in this pair.
Default choice: Armodafinil. Wider use case, a Tier-A evidence outcome catalogued, and broader goal coverage. Reach for Epitalon only if your priority sits squarely in the goals it owns above.
This verdict is generated from each compound's schema (goals, legal status, evidence outcomes, dosing route). It updates automatically as our compound data evolves; the deeper read sits on each individual compound page.
Common questions
What is the difference between Armodafinil and Epitalon?
Armodafinil and Epitalon differ in category (pharmaceutical vs peptide), mechanism, and typical dosing. See the side-by-side table for full details.
Which has a longer half-life, Armodafinil or Epitalon?
Armodafinil half-life is 15 hours; Epitalon half-life is 0.5 hours.
Can you stack Armodafinil with Epitalon?
Stack compatibility depends on mechanism overlap, legal status, and individual response. Check each compound page for specific interactions and contraindications before combining.
Go deeper